Guardant Health (GH) – Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Guardant Health (NASDAQ: GH) in the last few weeks:

• 7/1/2026 – Guardant Health had its price target raised by BTIG Research from $160.00 to $190.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Guardant Health had its price target raised by Guggenheim from $135.00 to $160.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Guardant Health is now covered by Sanford C. Bernstein. They set an “outperform” rating and a $175.00 price target on the stock.
• 6/25/2026 – Guardant Health was upgraded by Sanford C. Bernstein to “strong-buy”.
• 6/24/2026 – Guardant Health was given a new $150.00 price target by UBS Group AG.
• 6/24/2026 – Guardant Health had its price target raised by Barclays PLC from $120.00 to $150.00. They now have an “overweight” rating on the stock.
• 6/11/2026 – Guardant Health is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $185.00 price target on the stock.
• 6/11/2026 – Guardant Health is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $185.00 price target on the stock.
• 6/8/2026 – Guardant Health had its price target raised by Mizuho from $135.00 to $175.00. They now have an “outperform” rating on the stock.
• 6/5/2026 – Guardant Health is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $165.00 price target on the stock.
• 6/5/2026 – Guardant Health is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $165.00 price target on the stock.
• 6/2/2026 – Guardant Health was upgraded by Evercore Inc from “in-line” to “outperform”. They now have a $160.00 price target on the stock.
• 6/2/2026 – Guardant Health is now covered by Wolfe Research. They set an “outperform” rating and a $150.00 price target on the stock.
• 6/1/2026 – Guardant Health was upgraded by Wolfe Research to “strong-buy”.
• 5/28/2026 – Guardant Health was downgraded by Guggenheim from “buy” to “buy”.
• 5/27/2026 – Guardant Health was given a new $160.00 price target by BTIG Research. They now have a “buy” rating on the stock.
• 5/26/2026 – Guardant Health had its price target raised by BTIG Research from $145.00 to $155.00. They now have a “buy” rating on the stock.
• 5/21/2026 – Guardant Health was given a new $127.00 price target by Piper Sandler.
• 5/21/2026 – Guardant Health had its “buy” rating reaffirmed by TD Cowen.
• 5/12/2026 – Guardant Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $135.00 price target on the stock.
• 5/8/2026 – Guardant Health had its price target raised by Barclays PLC from $115.00 to $120.00. They now have an “overweight” rating on the stock.
• 5/8/2026 – Guardant Health had its price target raised by JPMorgan Chase & Co. from $130.00 to $135.00. They now have an “overweight” rating on the stock.

Insider Transactions at Guardant Health

In related news, insider John G. Saia sold 20,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total value of $2,130,200.00. Following the completion of the sale, the insider directly owned 45,950 shares in the company, valued at $4,894,134.50. This trade represents a 30.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Meghan V. Joyce sold 10,000 shares of Guardant Health stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the transaction, the director directly owned 11,183 shares of the company’s stock, valued at $1,420,017.34. The trade was a 47.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 712,513 shares of company stock worth $90,921,587. 5.60% of the stock is currently owned by corporate insiders.

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.